Use of genetically engineered strain VNP20009-M in preventing and treating cancer metastasis
AssigneeGuangzhou Sinogen Pharmaceutical Co., Ltd
InventorsAllan Zijian Zhao, Sujin Zhou, Yan Lin, Zhenggang Zhao, Fanghong Li
Life of this patent
Estimating the term…
Abstract
The present disclosure provides uses of genetically engineered attenuated Salmonella typhimurium strain VNP20009-M in preventing and treating cancer metastasis. The genetically engineered strain VNP20009-M is targeted to cancer cells and has a significant effect of inhibiting metastasis and growth. VNP20009-M can be used to prepare medicaments for the prevention and treatment of tumor metastasis.
Claims6
A method for treating metastasis of a cancer in a human subject, the method comprising administering a therapeutically effective amount of a genetically engineered strain VNP20009-M to the human subject, wherein the genetically engineered strain VNP20009-M is an attenuated Salmonella typhimurium VNP20009 comprising an L-methioninase gene, wherein the VNP20009-M is administered intravenously or intratumorally, and wherein the cancer is prostate cancer or liver cancer.
Dependencies are inferred from the claim text.